% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Ringborg:307270,
      author       = {U. Ringborg and J. von Braun and J. Celis and A. Berns and
                      M. Baumann$^*$ and T. Albreht and N. Abou-Zeid and V.
                      Bagnato and C. Brandts and C.-J. Chen and M. di Pietro and
                      M. Dosanjh and T. Dubois and A. Eggermont and A. Eggert and
                      I. Ernberg and S. Faithfull and J. Förner and S.
                      Fröhling$^*$ and M. Heitor and L. Hood and W. Jiang and B.
                      Jönsson and R. Kannan and M. Leptin and S. Li and P.
                      Lindgren and D. Lowy and J. Ma and A. Markham and P. Nagy
                      and S. Oberst and M. I. Parker and D. Rodin and K. Ryan and
                      J. Schüz and R. Sullivan and J. Tabernero and P. Turkson
                      and O. Várhelyi and H. Varmus and C. Wang and E. Weiderpass
                      and N. Wilking},
      title        = {{D}eveloping evidence-based, cost-effective {P}4 cancer
                      medicine for driving innovation in prevention, therapeutics,
                      patient care and reducing healthcare inequalities:
                      {P}roceedings from a conference organised by the
                      {P}ontifical {A}cademy of {S}ciences and the {E}uropean
                      {A}cademy of {C}ancer {S}ciences, held in {V}atican {C}ity,
                      {M}ay 22-23, 2025.},
      journal      = {Molecular oncology},
      volume       = {nn},
      issn         = {1574-7891},
      address      = {Hoboken, NJ},
      publisher    = {John Wiley $\&$ Sons, Inc.},
      reportid     = {DKFZ-2025-02963},
      pages        = {nn},
      year         = {2025},
      note         = {epub / Patient Advisory Council of the German Cancer
                      Research Center (DKFZ) and NCT Patient Research Council,
                      Heidelberg, Germany.W075 Center for advanced Cancer studies},
      abstract     = {The cancer problem is expanding, particularly in low- and
                      middle-income countries (LMICs). Preventive measures can
                      reduce the incidence by $40-50\%,$ and cure rates have
                      increased during the past decades in a number of cancers.
                      However, optimizing prevention programmes and increasing
                      cure rates of cancer remain significant research challenges.
                      The main focus of the conference was on P4 Cancer Medicine
                      (Predictive, Preventive, Personalized and Participatory), a
                      comprehensive strategy encompassing Health-Related Quality
                      of Life (HRQoL) research, aiming to enhance the well-being
                      of patients and individuals at risk. Addressing the cancer
                      problem requires two key elements: translational cancer
                      research and the development of relevant infrastructures. A
                      Comprehensive Cancer Centre (CCC) acts as an innovation hub
                      by integrating high-quality, multidisciplinary therapy and
                      care, with healthcare-dependent prevention, research, and
                      education. The United States has been at the forefront,
                      providing quality-assured CCCs and the Cancer Moonshot for
                      strategic cancer research. The EU has followed with the
                      European Research Council for basic research, the European
                      Innovation Council to boost disruptive innovation, and two
                      EU initiatives on cancer, Europe's Beating Cancer Plan
                      (EBCP) and the Mission on Cancer. The increasing complexity
                      of cancer biology and technologies presents both a research
                      challenge and a healthcare demand. For most patients, a CCC
                      is not available. A critical discussion focused on quality
                      assurance of healthcare outside the catchment area of a CCC
                      and involving patients in clinical research. The strategic
                      deployment of resources to support collective healthcare
                      efforts and research aimed at reducing the cancer problem
                      was discussed with representatives from the United States,
                      EU, Africa, China, India and Taiwan. Analyses of
                      translational cancer research have revealed important gaps
                      in implementing innovations, assessment of clinical
                      effectiveness, HRQoL, outcome and health economics research.
                      The increased release of new anticancer agents over the last
                      25 years, accompanied by insufficient information on
                      clinical benefits, presents both an economic and ethical
                      problem. Direct healthcare costs have increased due to
                      expenses for anticancer agents for the treatment of patients
                      with incurable diseases. Evidence-based treatment based on
                      HRQoL research is an unmet need. Basic/preclinical research
                      aimed at increasing the cure rate should identify new,
                      broader targets for therapy and develop extended diagnostic
                      technologies for stratifying patients, to inform innovative
                      clinical trials. Present research strategies convert cancer
                      to a chronic disease, a growing burden for the healthcare
                      systems. The increasing complexity of cancer biology and
                      technology, the growing need for translational cancer
                      research, and the demand for supporting infrastructures
                      underscore the importance of international collaborations
                      between CCCs. However, funding for cancer research is not
                      currently aligned to reduce the cancer problem. While public
                      funding for cancer research doubled between 2005 and 2024,
                      the pharmaceutical industry's spending on cancer research
                      increased tenfold. Increasing funding by public and
                      non-profit funding organizations is mandatory. Education is
                      another significant need, but it is currently fragmented and
                      underfunded. The last session of the conference summarized
                      the strategies in a Statement with a strong emphasis on
                      global collaboration addressing the growing cancer burden
                      and pronounced inequalities. Expanding partnerships and
                      fostering innovative, multidisciplinary approaches to cancer
                      prevention, therapeutics/care, as well as research, are not
                      just urgent but essential steps towards reducing incidence,
                      increasing cure rates and enhancing the well-being of cancer
                      patients. Data-driven cancer medicine is currently under
                      development, and modern communication technologies for
                      diagnostics may facilitate interactions across geographical
                      distances. A global cancer research agenda can become a
                      model of solidarity, sustainability, and ethical
                      responsibility.},
      keywords     = {Comprehensive Cancer Center (Other) / cancer prevention
                      (Other) / cancer therapeutics/care (Other) / inequalities
                      (Other) / science policy (Other) / structuring translational
                      cancer research (Other)},
      cin          = {E220 / B340},
      ddc          = {610},
      cid          = {I:(DE-He78)E220-20160331 / I:(DE-He78)B340-20160331},
      pnm          = {319H - Addenda (POF4-319H)},
      pid          = {G:(DE-HGF)POF4-319H},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41397948},
      doi          = {10.1002/1878-0261.70179},
      url          = {https://inrepo02.dkfz.de/record/307270},
}